Developing Antidrug Antibodies to Infliximab or Adalimumab in HLA DQ Alleles

Overview

About this study

The purpose of this study is to develop a laboratory test to determine if an individual is at risk of developing antibodies to one of these two monoclonal therapies based on their HLA-DQ genotype.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Previously received a positive result from either the antibodies to infliximab (INXAB) OR antibodies to adalimumab (ADLAB) test

Exclusion Criteria:

Does not meet inclusion criteria, does not provide consent to participate.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/13/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Maria Alice Willrich, Ph.D.	Open for enrollment	Contact information: Susan Holtegaard (507) 284-8359 Holtegaard.Susan@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Maria Alice Willrich, Ph.D.

Open for enrollment

Contact information:

Susan Holtegaard

(507) 284-8359

Holtegaard.Susan@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials